Back

Gender-related differences in efficacy, safety and adherence of PCSK9 inhibitors in real-world clinical practice: insights from the AT-TARGET-IT Registry

30 August 2026 (10:15 - 11:00)
Organised by: Logo
Congress Presentation Part of: Lipid lowering and cardiovascular outcomes Lipid-Lowering Agents ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Professor Pasquale Perrone-Filardi

University of Naples Federico II, Naples (Italy)

6 More presentations in this session

Presentation thumbnail
Sustained combination lipid-lowering therapy determines durability of LDL-C <55 mg/dL after ACS: a structured implementation study (2022–2026)
Doctor K. Mahajan (Mandi, IN)
Abstract
Presentation thumbnail
EDP167, an ANGPTL3-target siRNA, showed favorable safety and lipid-lowering potential in Chinese healthy adult volunteers and subjects with mild dyslipidemia
Doctor B. Jiang (Hangzhou, CN)
Abstract
Presentation thumbnail
Statin therapy and 1-year mortality in non-ischaemic acute myocardial injury: a dual-cohort study
Doctor T. Yang (Tianjin, CN)
Abstract
Presentation thumbnail
Pooled on treatment lipid lowering efficacy of the CETP inhibitor obicetrapib in phase III trials
Mr M. De Kleer (Amsterdam, NL)
Abstract
Presentation thumbnail
Effect of apolipoprotein B reduction on major adverse cardiovascular events in randomized controlled trials of triglyceride-lowering therapies: systematic review and exploratory meta-regression
Doctor M. Sobral Domingues (Lisbon, PT)
Abstract

Access the full session

Session thumbnail
Lipid lowering and cardiovascular outcomes

The Event

Event poster

ESC Congress 2026

30 August 2026 10:15 CET
You may be interested in
thumbnail
Congress Presentation
PCSK9 inhibitors: effectiveness of treatment and changes in background lipid-lowering therapy in a real world Italian population. The AT-TARGET-IT study
26 August 2022
thumbnail
Webinar
Women's heart health: what you need to know to help your female patients care for themselves better
16 June 2022
thumbnail
Congress Presentation
Sex-specific drug-target Mendelian randomisation on the effects of lipid-modifying targets on cardiovascular disease
4 April 2025
thumbnail
Congress Presentation
Undertreatment of women with lipid-lowering therapies in four European countries: results from the prospective, non-interventional MILOS Study
30 August 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources